BB Healthcare Trust PLC Issue of Equity (0945R)

TIDMBBH

RNS Number : 0945R

BB Healthcare Trust PLC

03 March 2021

 
 
   3 March 2021 
 
   NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, 
    TO THE UNITED STATES, AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, 
    JAPAN OR ANY MEMBER STATE OF THE EEA (FOR THE AVOIDANCE OF DOUBT, 
    THIS DOES NOT INCLUDE THE UK) OR TO ANY NATIONAL, RESIDENT OR CITIZEN 
    OF AUSTRALIA, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY 
    MEMBER STATE OF THE EEA (FOR THE AVOIDANCE OF DOUBT, THIS DOES NOT 
    INCLUDE THE UK) 
 
                            BB Healthcare Trust plc 
 
                            Issue of Ordinary Shares 
 
   BB Healthcare Trust plc (the "Company") announces that it has today 
    issued 250,000 of its ordinary shares of one penny each ("Ordinary 
    Shares") pursuant to its block listing facility. The Ordinary Shares 
    will be issued at a price of 186.08 pence per Ordinary Share, a 
    premium to the prevailing net asset value ("cum income") per Ordinary 
    Share. 
 
   Following the issue of Ordinary Shares, the Company's issued share 
    capital will comprise (510,045,455) Ordinary Shares and this is 
    the total number of Ordinary Shares with voting rights in the Company. 
    This figure (510,045,455) may be used by shareholders as the denominator 
    for the calculations by which they will determine if they are required 
    to notify their interest in, or a change to, their interest in the 
    Company under the Financial Conduct Authority's Disclosure Guidance 
    and Transparency Rules. 
 
   The Company's LEI is: 213800HQ3J3H9YF2UI82 
 
   For further information please contact: 
 
   Bellevue Asset Management (UK) Ltd. 
   Mark Ghahramani 
   Telephone: [phone] 
 
   J.P. Morgan Cazenove 
   James Bouverat (Sales) 
   Telephone: [phone] 
 
   Alvarium Securities Limited 
   Mark Thompson [phone] 
   Eddie Nissen [phone] 
   Oliver Kenyon [phone] 
 
 
 
   Disclaimer 
 
   This announcement does not constitute a prospectus relating to the 
    Company and does not constitute, or form part of, any offer or invitation 
    to sell or issue, or any solicitation of any offer to purchase or 
    subscribe for, any shares in the Company in any jurisdiction nor 
    shall it, or any part of it, or the fact of its distribution, form 
    the basis of, or be relied on in connection with or act as any inducement 
    to enter into, any contract therefore. 
 
   J.P. Morgan Cazenove and Alvarium Securities Limited, which are 
    authorised and regulated by the Financial Conduct Authority, are 
    acting for the Company only in connection with the matters described 
    in this announcement and are not acting for or advising any other 
    person, or treating any other person as their client, in relation 
    thereto and will not be responsible for providing the regulatory 
    protection afforded to clients of Alvarium Securities Limited and 
    J.P. Morgan Cazenove or advice to any other person in relation to 
    the matters contained herein. 
 
   The shares of the Company have not been and will not be registered 
    under the US Securities Act of 1933, and may not be offered or sold 
    in the United States absent registration or an applicable exemption 
    from the registration requirements. Moreover, the shares of the 
    Company have not been, nor will they be, registered under the applicable 
    securities laws of Australia, Canada, the Republic of South Africa, 
    Japan or any member state of the EEA (other than the United Kingdom). 
    Further, the Company will not be registered under the US Investment 
    Company Act of 1940, as amended. Subject to certain exceptions, 
    the shares of the Company may not be offered or sold in the United 
    States, Australia, Canada, the Republic of South Africa, Japan or 
    any member state of the EEA (other than the United Kingdom or to 
    professional investors in Ireland) or to, or for the account or 
    benefit of, any national, resident or citizen of the United States, 
    Australia, Canada, the Republic of South Africa, Japan or any member 
    state of the EEA (other than the United Kingdom or to professional 
    investors in Ireland). The share issuance programme, and the distribution 
    of this announcement, in other jurisdictions may be restricted by 
    law and the persons into whose possession this announcement comes 
    should inform themselves about, and observe, any such restrictions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

IOEFLFSDVRIVIIL

(END) Dow Jones Newswires

March 03, 2021 12:47 ET (17:47 GMT)